» Articles » PMID: 26810282

Decreased Level of Osteopontin in Children with Allergic Rhinitis During Sublingual Immunotherapy

Overview
Specialty Pediatrics
Date 2016 Jan 27
PMID 26810282
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Sublingual immunotherapy (SLIT) is proven to be very effective in the treatment of allergic rhinitis (AR), but its regulatory mechanism and biomarkers for predicting efficacy are still unknown. Osteopontin (OPN), as a recently described Th2 inflammation related protein, plays key role in the pathogenesis of AR. The aim of this study was to identify the expression and role of OPN during SLIT in children.

Methods: Fifty house dust mite (HDM)-sensitized children with AR were enrolled in this study. AR children received HDM allergen extract or placebo for SLIT. Serum of different time points during treatment was collected and used for enzyme-linked immuno sorbent assay (ELISA) of OPN and related cytokines, respectively. Peripheral blood mononuclear cells from children after SLIT or placebo treatment were collected and stimulated with HDM with or without OPN/anti-OPN after one year's treatment.

Results: Our results showed that expression of OPN protein was decreased after one year's therapy. The decreased OPN expression was positively related to decreased Th2 cytokines and negatively related to enhanced IL-10 and TGF-β expression. In vitro experiments confirmed that children received SLIT treatment showed decreased production of Th2 cytokines by PBMCs after HDM stimulation.

Conclusion: During SLIT, decreased OPN expression was related to low Th2 cytokine expression and enhanced IL-10 and TGF-β expression. High serum OPN expression predicts poor treatment efficacy. OPN may be used as a biomarker for SLIT treatment.

Citing Articles

The evidence for commercial house dust mite immunotherapy products: A pragmatic systematic review with narrative synthesis.

West T, Katelaris C J Allergy Clin Immunol Glob. 2024; 3(3):100255.

PMID: 39092213 PMC: 11292502. DOI: 10.1016/j.jacig.2024.100255.


Increased Nasal Blimp1 + Treg Cells After Sublingual Immunotherapy Reflect the Efficacy of Treatment in Allergic Rhinitis.

Pan Y, Zhang X, Geng H, Yu Y, Liu J, Li M Adv Ther. 2024; 41(4):1698-1710.

PMID: 38443650 DOI: 10.1007/s12325-024-02819-8.


Immune Cell Alterations and PI3K-PKB Pathway Suppression in Patients with Allergic Rhinitis Undergoing Sublingual Immunotherapy.

Zhang X, Wu G, Ma X, Cheng L Adv Ther. 2024; 41(2):777-791.

PMID: 38169061 DOI: 10.1007/s12325-023-02747-z.


Efficacy and safety of sublingual versus subcutaneous immunotherapy in children with allergic rhinitis: a systematic review and meta-analysis.

Yang J, Lei S Front Immunol. 2024; 14:1274241.

PMID: 38162647 PMC: 10757840. DOI: 10.3389/fimmu.2023.1274241.


The Role and Clinical Relevance of Osteopontin in Allergic Airway Diseases.

Liu Y, Fu L, Liu Z J Clin Med. 2023; 12(6).

PMID: 36983433 PMC: 10057512. DOI: 10.3390/jcm12062433.